(UPDATE) AN antibody cocktail for the treatment of Covid-19 among adults and adolescents has been approved in the European Union and Japan, according to its manufacturer, AstraZeneca.
The AZD7442 cocktail combines two long-acting antibodies — tixagevimab and cilgavimab — which was derived from B-cells donated by convalescent patients after infection from Covid-19.
Already have an active account? Log in here.
Continue reading with one of these options:
Continue reading with one of these options:
Premium + Digital Edition
Ad-free access
P 80 per month
(billed annually at P 960)
- Unlimited ad-free access to website articles
- Limited offer: Subscribe today and get digital edition access for free (accessible with up to 3 devices)
TRY FREE FOR 14 DAYS
See details
See details
If you have an active account, log in
here
.